A Study to Determine Dose Safety Tolerability and Efficacy of CC-220 Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 MonoT, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 MonoT, CC-220 in combination with DEX (DoubleT) for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.
A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY AND TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-220 MONOTHERAPY, IN COMBINATION WITH DEXAMETHASONE, AND IN COMBINATION WITH DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
- ClinicalTrials.gov Identifier: NCT02773030
- Protocol Number: 19-054
- Principal Investigator: Jacalyn Rosenblatt
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required